Volume 13, Issue 3 (Aug 2025)
Res Mol Med (RMM) 2025, 13(3): 0-0 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Naderi Alizadeh M, Rahimlou M E, Rahimlou E, Vahedian V, Gharibi M, Soltani N et al . Apatinib as a Potentials Therapeutic Agent in Breast Cancer Treatment with a Focus on Clinical Trials: a State-of-the-art Study. Res Mol Med (RMM) 2025; 13 (3)
URL: http://rmm.mazums.ac.ir/article-1-628-en.html
URL: http://rmm.mazums.ac.ir/article-1-628-en.html
Mohammad Naderi Alizadeh1 
, Mohammad Ehsan Rahimlou2 , Elham Rahimlou2 , Vahid Vahedian3 , Madi Gharibi4 , Nahal Soltani2 , Nazila Fathi Maroufi5
, Mohammad Ehsan Rahimlou2 , Elham Rahimlou2 , Vahid Vahedian3 , Madi Gharibi4 , Nahal Soltani2 , Nazila Fathi Maroufi5
1- Functional Neurosurgey Research Center, Shohada Tajrish Comprehensive Neurosurgical Center of Excellence, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
2- Department of Medical Laboratory Sciences, Faculty of Medicine, Islamic Azad University (IAU), Marand, Iran
3- Department of Internal Medicine,Division of Hematology and Cellular Therapy/LIM-31,Clinical Hospital, Faculty of Medicine, University of Sao Paulo,Brazil & Comprensive Center for Translational and Precision Oncology, Sao Paulo State Cancer Institue (ICESP), Sao Paulo,Brazil.
4- Department of pharmacy, Faculty of Pharmacy, University of Ankara, Ankara, Turkey
5- Department of Biochemistry and Clinical Laboratories, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran ,n.fathi6788@gmail.com
2- Department of Medical Laboratory Sciences, Faculty of Medicine, Islamic Azad University (IAU), Marand, Iran
3- Department of Internal Medicine,Division of Hematology and Cellular Therapy/LIM-31,Clinical Hospital, Faculty of Medicine, University of Sao Paulo,Brazil & Comprensive Center for Translational and Precision Oncology, Sao Paulo State Cancer Institue (ICESP), Sao Paulo,Brazil.
4- Department of pharmacy, Faculty of Pharmacy, University of Ankara, Ankara, Turkey
5- Department of Biochemistry and Clinical Laboratories, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran ,
Abstract: (43 Views)
Breast cancer is the most important cancer in females. The treatment of this cancer is one of the challenges facing the world health system. Metastasis and invasion of cancer cells are the basis of the difficulty of treatment in this cancer. On the other hand, the formation of new vessels or angiogenesis facilitates metastasis in cancer patients. Therefore, researchers are trying to find new therapeutic drugs. One of the important factors in the processes of angiogenesis and metastasis is vascular endothelial growth factor (VEGF) and its receptor (VEGFR). Agents that can inhibit this molecule and its receptor will have helpful therapeutic potential for treating breast cancer. Apatinib is a drug that has attracted the attention of cancer researchers in the last decade, and many studies have been conducted on the effectiveness of this drug in the field of cancer treatment especially breast cancer. In this review article, we aimed to review the therapeutic potential of Apatinib in-vivo studies, animal models, with a focus on clinical trials.
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
This is an open access article distributed under the terms of the Creative Commons Attribution License (CC-By-NC), which permits use, distribution, and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
Contact Information
